Last reviewed: May 23, 2026 · UnitedHealthcare, Aetna, Cigna, Humana · Methodology
Working playbooks for the four major specialty drug payers in 2026 — UnitedHealthcare, Aetna, Cigna, and Humana — written for patient care coordinators, prior authorization specialists, and billers who need to ship a clean PA today. Each playbook covers the payer’s PA workflow, the relevant provider portals, fax numbers by drug class, peer-to-peer escalation, site-of-care policy, biosimilar mandates, specialty pharmacy network, step therapy requirements, common denial patterns, reauthorization intervals, and per-payer FAQs.
Each card below links to a full operational playbook for one payer. Card content summarizes the strategic posture (PBM, specialty pharmacy, biosimilar aggressiveness, MA vs commercial weight) and the single most important workflow gotcha for each payer.
UHC’s ecosystem splits across UHCProvider.com (medical-benefit PA), OptumRx (pharmacy-benefit specialty PA), and Optum Specialty Pharmacy (white-bag dispensing) — three portals with the same parent (Optum / UnitedHealth Group) but separate workflows. UHC has the most aggressive biosimilar substitution mandate among the four (bevacizumab, trastuzumab, infliximab, rituximab, pegfilgrastim, and now adalimumab via Cordavis) and the most aggressive site-of-care steerage (Outpatient Hospital Site of Care Review program).
Aetna’s specialty drug ecosystem is anchored by the CVS Health alignment: CVS Caremark as PBM, CVS Specialty as primary specialty pharmacy, and Cordavis (a CVS Health subsidiary) for biosimilar private-label distribution. Provider workflows route through Aetna’s provider portal and Availity. Aetna’s biosimilar posture is middle-of-the-pack — firm but not UHC-aggressive — with Cordavis-driven Humira biosimilar substitution as the marquee 2024+ initiative.
Cigna’s ecosystem runs through the Evernorth health services arm: Express Scripts (PBM) and Accredo (specialty pharmacy) are the operational anchors. Cigna’s biosimilar posture is firm but less aggressive than UHC’s; Accredo’s clinical management model emphasizes therapy adherence and patient outreach. Workflows route through CignaforHCP.com and Express Scripts / Accredo portals for the pharmacy-benefit side.
Humana is heavily Medicare Advantage — one of the largest MA plans nationally — and exited commercial group ACA in 2024. The dominant operational question on a Humana PA is Part B (clinician-administered, medical buy-and-bill) vs Part D (self-administered, pharmacy via CenterWell). CMS Step Therapy on MA Part B applies aggressively; CED registry enrollment is required for amyloid Alzheimer’s mAbs (Leqembi, Kisunla); TRICARE workflows are entirely separate via Humana Military.
Scenarios based on the patient’s insurance card. Click through to the right playbook.
All UnitedHealth Group products route through the UHC ecosystem with OptumRx as PBM and Optum Specialty Pharmacy as captive SP. Surest is on a separate stack but is a UHC product. UMR is the UHC third-party administrator brand.
All Aetna products route through Aetna provider workflows with CVS Caremark as PBM and CVS Specialty as primary SP. Aetna Better Health is the Medicaid managed-care book; Aetna Medicare is the MA-PD book.
Cigna and its operating subsidiaries route through Cigna provider workflows with Express Scripts as PBM and Accredo as specialty pharmacy (both under the Evernorth banner). Cigna Healthspring is the legacy MA brand; Allegiance and Loomis are TPA brands.
All Humana products route through Humana workflows with Humana Pharmacy Solutions as PBM and CenterWell Specialty Pharmacy as primary SP. TRICARE East is administered by Humana Military and operates on a separate stack (Express Scripts handles TRICARE pharmacy). The first operational question on any Humana PA is Part B vs Part D.
BCBS plans operate as 33 independent licensee organizations with significant variation in PA workflow, PBM contracting, and specialty pharmacy network by state. There is no single “BCBS playbook” that fits all licensees.
→ BCBS playbooks are a 2026 Sprint 2 deliverable. In the meantime, route through the patient’s specific Blue plan provider portal and the licensee’s published PA criteria.
Original Medicare beneficiaries are not on any of these four MA plans; PA flows directly through the relevant MAC (Medicare Administrative Contractor) under the applicable Local Coverage Determination, with no commercial / MA payer in the loop.
→ None of these playbooks apply directly. Use the MAC LCD and any required modifiers (e.g., KX for LCD-driven drugs).
Strategic differences across the four major specialty drug payers in 2026. Each playbook has the per-payer operational specifics; this table is for setting expectations before you open a case.
| Dimension | UnitedHealthcare | Aetna | Cigna | Humana |
|---|---|---|---|---|
| Book of business emphasis | Commercial-heavy; large MA; Community Plan (Medicaid) | Commercial + MA; CVS-aligned | Commercial + MA; Evernorth-aligned | MA-heavy (~80%+); exited commercial group ACA 2024 |
| PBM | OptumRx | CVS Caremark | Express Scripts (Evernorth) | Humana Pharmacy Solutions (HPS) |
| Primary specialty pharmacy | Optum Specialty Pharmacy | CVS Specialty | Accredo (Evernorth) | CenterWell Specialty Pharmacy |
| Biosimilar mandate aggressiveness | Most aggressive | Moderate; Cordavis-driven on Humira | Firm; Evernorth-coordinated | CMS-driven on MA Part B; tier-driven on Part D |
| Site-of-care steerage (commercial) | Outpatient Hospital Site of Care Review (most aggressive) | Moderate; per medical policy bulletins | Moderate; Specialty Drug Management framework | Least aggressive commercial |
| Site-of-care steerage (MA Part B) | CMS LCD + UHC overlay | CMS LCD + Aetna overlay | CMS LCD + Cigna overlay | CMS LCD-driven (dominant framework) |
| Primary PA portal (medical benefit) | UHCProvider.com PAAN + Availity | Aetna provider portal + Availity | CignaforHCP.com + Availity | HumanaProvider.com + Availity |
| Primary PA portal (pharmacy benefit) | OptumRx + CoverMyMeds | CVS Caremark + CoverMyMeds | Express Scripts + CoverMyMeds | CenterWell + CoverMyMeds |
| Marquee workflow gotcha | OptumRx vs Optum Specialty vs PAAN portal selection | CVS Caremark vs CVS Specialty distinction | Express Scripts vs Accredo distinction | Part B vs Part D channel miscall |
| Appeals structure (commercial) | L1 internal → L2 internal → IRO | L1 internal → L2 internal → IRO | L1 internal → L2 internal → IRO | Limited commercial book; per state of issue |
| Appeals structure (MA) | Plan Reconsideration → IRE (C2C / Maximus) → ALJ | Plan Reconsideration → IRE → ALJ | Plan Reconsideration → IRE → ALJ | Plan Reconsideration → IRE (C2C / Maximus) → ALJ |
“Most aggressive”, “moderate”, and “least aggressive” characterize the payer’s posture relative to the other three on the comparison axis; they are not absolute. CMS-driven means the dominant framework is set by Medicare Advantage program rules (Step Therapy guidance, NCDs, LCDs) rather than payer-specific commercial medical policy. See each playbook’s Sources section for the authoritative references.
Payer PA is one half of the workflow; the other half is getting the claim line shape right. These references pair with the per-payer playbooks above.
Payer specialty drug policy is a moving target. UHC’s biosimilar mandate expanded meaningfully in 2024 with Cordavis-driven Humira substitution; Aetna’s Cordavis routing followed; Cigna’s Evernorth coordination tightened through 2024-2025; Humana’s commercial book contracted with the 2024 ACA group exit and the dominant operational frame shifted to MA Part B with CMS Step Therapy enforcement. New CMS rules (the 2023+ NCD on amyloid mAbs with CED registry framework, the expanded MA Part B step therapy guidance) flow through to MA operations within a quarter or two.
We update each playbook on a published cadence (PA workflow, portals, fax numbers, common denials, specialty pharmacy network are reviewed monthly; biosimilar policy, step therapy, FAQ, and reauth intervals are reviewed quarterly) and on an event-driven basis when a payer or CMS rule change crosses our reader-feedback channel. The CareCost editorial team reviews each playbook on publication and on each material update; the full process is in the Editorial Policy. Every playbook lists its sources and notes that fax numbers and portal URLs are illustrative and must be verified on the payer’s current provider portal before submission.
Coming in Sprint 2: Blue Cross Blue Shield licensee playbook framework (for the larger Blues including Anthem / Elevance, Highmark, Florida Blue, BCBS of Massachusetts, BCBS of Illinois / Texas via HCSC), plus per-state Medicaid managed-care playbooks for the highest-volume specialty drug states. Reach out at editorial@carecostestimate.com if there’s a payer or licensee where your team would value coverage sooner.